Obesity’s Future: GLP-1s - Game-Changing Weight Loss with Dr. Spencer Nadolsky

Dr. Spencer Nadolsky joins Ethan on the American Glutton Podcast to dive into the revolutionary impact of GLP-1 drugs on obesity and cardiometabolic health, exploring their benefits, risks, and societal implications. From debunking myths about weight loss to discussing emerging treatments like myostatin inhibitors, they tackle the science and real-world applications head-on. The conversation also touches on the future of these medications, their potential to prevent weight gain, and the importance of combining them with lifestyle changes like resistance training.SHOW HIGHLIGHTS00:00 - Introduction and Catching Up00:35 - Obesity as a Choice and GLP-1 Drugs01:58 - Misuse of GLP-1s and Social Media Hype05:08 - The Science Behind GLP-1 and Incretin Effect07:37 - How GLP-1 Drugs Work for Weight Loss10:00 - Benefits vs. Risks of GLP-1 Drugs11:57 - Common Side Effects and Nausea Discussion13:15 - Fatigue and Anhedonia as Side Effects14:54 - Fat Cell Memory and Weight Regain17:41 - GLP-1s as a Breakthrough for Obesity19:33 - Comparing Risks of GLP-1s to Other Drugs20:24 - Big Pharma and Advisory Boards23:57 - Importance of Protein and Resistance Training27:34 - Myostatin Inhibitors and Muscle Growth31:39 - Timeline for New Drug Approvals33:31 - Drug Costs and Accessibility37:51 - Comparing GLP-1 Drugs and Zepbound39:57 - Glucagon and Triple Agonist Drugs41:58 - Future of GLP-1s in Preventing Weight Gain43:43 - Microdosing and Anti-Inflammatory Effects44:33 - GLP-1s and Type 1 Diabetes Considerations48:50 - Historical Context and Obesity Trends52:37 - Moralizing Weight and Pharmaceutical Solutions54:03 - Closing Thoughts and Future Support Hosted on Acast. See acast.com/privacy for more information.

There are no comments yet.

Please log in to write the first comment.